Characteristics of Multi-Regional Clinical Trials Conducted in Asia, Focusing on Japan’s Participation and Small/Medium Companies-Sponsored Trials
Authors:
- 16 July 2025
- journal article
- research article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 59 (6) , 1245-1252
Abstract
Background Less participation by Japan in multi-regional clinical trials (MRCTs) is one of concerns that leads to drug loss in Japan, but the characteristics of Japan’s participation in MRCTs have not been well studied. Purpose This study investigated Japan’s situation in global drug development by characterizing its participation in MRCTs compared with East and South-East Asian countries/regions, with a focus on MRCTs sponsored by small-medium companies to discuss necessary measures in further promoting drug development in Japan. Methods Data from MRCTs conducted in East and South-East Asia during the period from January 1, 2013 to December 31, 2022 were analyzed. Results Japan’s participation in MRCTs conducted in Asia (East Asia and South-East Asia) was limited. In particular, Japan participated in only 15–16% of MRCTs sponsored by Small/Medium-pharma (mainly US-based companies), with even less participation in Early Phase MRCTs. Japan’s participation in MRCTs was markedly lower than other Asian countries/regions such as Singapore, South Korea, and Taiwan, although it was relatively higher in MRCTs that targeted neoplasms compared with other diseases. Conclusion Results of this study raise significant concern about future potential drug loss in Japan. It is urgent to increase the participation of Japan in MRCTs in order to continuously provide new globally developed drugs to patients in Japan. For that purpose, an integrated approach that includes continuous improvement in pharmaceutical regulations and the clinical trial environment, as well as market attractiveness, will be necessary in parallel with strengthening of collaborations between Japan and other Asian countries/regions.Keywords
Funding Information
- Research grant on regulatory science of pharmaceuticals and medical devices from the Ministry of Health, Labour and Welfare (23KC2014)
This publication has 18 references indexed in Scilit:
- Simultaneous Global Drug Development and Multiregional Clinical Trials (MRCT): 5 Years After Implementation of ICH E17 GuidelinesTherapeutic Innovation & Regulatory Science, 2024
- Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based CompaniesTherapeutic Innovation & Regulatory Science, 2024
- Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseasesDrug Discovery Today, 2023
- Characteristics of Asian Participation in Multi-regional Clinical Trials Reviewed for Drug Approval in Japan: Opportunities for Collaboration Between South-East Asia, East Asia, and JapanTherapeutic Innovation & Regulatory Science, 2023
- Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the USTherapeutic Innovation & Regulatory Science, 2023
- Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East AsiaTherapeutic Innovation & Regulatory Science, 2022
- Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory AnalysisClinical Pharmacology & Therapeutics, 2020
- Innovation in oncology clinical trial designCancer Treatment Reviews, 2019
- Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?International Journal of Clinical Oncology, 2015
- Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in JapanClinical Pharmacology & Therapeutics, 2013